TAVT-18

TAVT-18 is a proprietary, novel powder formulation of sirolimus developed to improve oral bioavailability and reduce inter-patient variability compared to existing sirolimus formulations. Sirolimus is an mTOR (mechanistic target of rapamycin) inhibitor with immunosuppressive and antineoplastic properties. TAVT-18 was specifically designed for pediatric use, particularly in infants with tuberous sclerosis complex (TSC), aiming to prevent or delay seizure onset by targeting the dysregulated mTOR pathway characteristic of TSC. Preclinical studies demonstrated that TAVT-18 achieves higher plasma concentrations and exposure than standard sirolimus formulations at lower doses, potentially offering improved efficacy and safety for this population[1][5][6].

Other names

sirolimus (as active ingredient)